CSPC Zhongqi Pharmaceutical Technology (Shijiazhuang) Co. Ltd. has identified proteolysis targeting chimeras (PROTACs) comprising an E3 ubiquitin ligase cereblon binding moiety coupled to an EGFR-targeting moiety via a linker reported to be useful for the treatment of non-small-cell lung cancer.
CSPC Zhongqi Pharmaceutical Technology (Shijiazhuang) Co. Ltd. has synthesized son of sevenless homolog 1 (SOS1) and GTPase KRAS (G12D mutant) inhibitors reported to be useful for the treatment of cancer.
Beigene Ltd. struck a global licensing deal with CSPC Zhongqi Pharmaceutical Technology (Shijiazhuang) Co. Ltd. worth up to $1.5 billion for its phase I selective methionine adenosyltransferase 2A (MAT2A) inhibitor, SYH-2039, which is being explored for solid tumors.
Beigene Ltd. struck a global licensing deal with CSPC Zhongqi Pharmaceutical Technology (Shijiazhuang) Co. Ltd. worth up to $1.5 billion for its phase I selective methionine adenosyltransferase 2A (MAT2A) inhibitor, SYH-2039, which is being explored for solid tumors.
CSPC Zhongqi Pharmaceutical Technology (Shijiazhuang) Co. Ltd. has described pyrimidine and nitrogen-containing 6-membered aromatic heterocyclic compounds acting as S-adenosylmethionine synthase isoform type-2 (Mat2A) inhibitors reported to be useful for the treatment of cancer.
CSPC Zhongqi Pharmaceutical Technology (Shijiazhuang) Co. Ltd. has patented spiro compounds acting as tyrosine-protein phosphatase nonreceptor type 11 (PTPN11) inhibitors reported to be useful for the treatment of cancer and cardiovascular and immunological disorders.
CSPC Zhongqi Pharmaceutical Technology (Shijiazhuang) Co. Ltd. has identified son of sevenless homolog 1 (SOS1)/GTPase KRAS (G12D mutant) interaction inhibitors reported to be useful for the treatment of cancer, cardiofaciocutaneous syndrome, Costello syndrome, neurofibromatosis type 1, Noonan syndrome and Legius syndrome (neurofibromatosis type 1-like syndrome).
